Moderna shares slip as William Blair cuts rating on valuation after rally

Moderna fell 3% in premarket trading after William Blair cut its rating to Market Perform from Outperform, saying the shares already price in an aggressive oncology trajectory after a 545% year-to-date rally and nearly 250% gain since August. The analyst estimates the valuation implies a 70%–75% probability of success across expanded indications; William Blair models $5.4 billion in peak melanoma sales shared equally with Merck. The Phase 2 INTERPATH-004 renal-cell carcinoma readout, expected in late 2026 or 2027, is a key catalyst, while expansion into other solid tumors faces clinical and biological risks.

Analysis

Valuation is now the catalyst

The risk/reward has shifted from “does the melanoma signal work?” to “can the platform deliver enough indications and throughput to justify expectations?” Personalized, patient-specific production creates a second hurdle after clinical efficacy: batch turnaround, quality control, and reliable scaling may limit addressable volume or erode economics. A facility tour can reassure on process, but is not evidence of commercial cost or capacity.

Over the next several weeks, the main risk is expectation compression rather than a change in trial facts: with much of the upside attributed to future indications, incremental operational or clinical uncertainty can weigh disproportionately on MRNA. Over 1–3 months, watch for evidence on manufacturing scalability and management’s framing of commercial boundaries. The larger 6–18 month catalyst remains renal data, with colder-tumor biology a meaningful extrapolation risk from melanoma. Merck shares potential upside through the combination, but the vaccine’s contribution is unlikely to have the same equity sensitivity for MRK as for Moderna.

Contrarian point: the downgrade may be right on valuation but early on biology; strong melanoma efficacy could support adoption even if expansion is narrower than bulls expect. Conversely, a positive trial is not enough if individualized supply cannot scale. Avoid treating the modeled peak-sales opportunity as realized revenue.

Key Decisions for Investors

• Underweight or trim MRNA rather than chase strength; the near-term setup has asymmetric downside if investors lower assumed probabilities of success across indications. Avoid an outright short immediately ahead of the November 12 facility tour, which could be a sentiment catalyst.
• Consider a defined-risk MRNA put spread only after checking implied volatility and event pricing; expensive volatility could make outright puts unattractive. Keep exposure sized for a potentially sharp rally on reassuring operational updates.
• Treat MRK as a lower-beta relative-value hedge, not a clean offset: its economics and equity sensitivity differ from Moderna’s. Any MRNA-short/MRK-long pair should be sized conservatively and reassessed if combination economics or trial responsibility changes.
• Falsifiers: credible evidence of scalable, repeatable manufacturing and broader tumor efficacy would weaken the underweight thesis. Watch for operational detail beyond facility presentation, renal trial updates, and any guidance that clarifies capacity, turnaround, or commercial reach.